Publication date: Mar 06, 2019
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme probe substrates using a probe cocktail, on an organic anion-transporting polypeptide/breast cancer resistance protein (OATP/BCRP) substrate using rosuvastatin and on a CYP2B6 substrate using bupropion. The effect of multiple oral doses of the moderate cytochrome P450 (CYP) inhibitor modafinil on encorafenib in combination with binimetinib will also be assessed. The study will have 2 treatment phases, a drug-drug interaction (DDI) phase followed by a post-DDI phase.
- Desensitization protocol for angioedema induced by encorafenib in a patient with metastatic melanoma.
- New Targeted Therapy Duo Provides Advantages in BRAF-Mutant Melanoma
- Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma